Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-25-000967
Filing Date
2025-02-11
Accepted
2025-02-11 20:45:32
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11368
2 d11598865_ex99-a.htm EX-35 4837
3 d11598865_ex99-b.htm EX-99 773
  Complete submission text file 0000919574-25-000967.txt   18857
Mailing Address 5 RADNOR CORPORATE CENTER SUITE 500 100 MATSONFORD RD RADNOR PA 19087
Business Address 5 RADNOR CORPORATE CENTER SUITE 500 100 MATSONFORD RD RADNOR PA 19087 484-801-4670
MARINUS PHARMACEUTICALS, INC. (Subject) CIK: 0001267813 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88269 | Film No.: 25611578
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022
Business Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022 2127025204
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by) CIK: 0001569064 (see all company filings)

EIN.: 453704500 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G